Printer Friendly

ALTEON AND MARION MERRELL DOW EXPAND COLLABORATION ON DRUGS FOR DIABETES AND AGING

 ALTEON AND MARION MERRELL DOW EXPAND COLLABORATION
 ON DRUGS FOR DIABETES AND AGING
 NORTHVALE, N.J., Dec. 13 /PRNewswire/ -- Alteon Inc. (NASDAQ: ALTN) today announced that Marion Merrell Dow Inc. (NYSE: MKC) has exercised an option to expand its existing strategic alliance with Alteon to include Europe and other selected world markets.
 In December of 1990, Alteon, formerly Geritech Inc., and Marion Merrell Dow formed a strategic alliance in North America to develop and commercialize Alteon's technology for therapeutics to treat the complications of diabetes and aging.
 Under the terms of the new agreement, Alteon and Marion Merrell Dow will expand the joint development of Alteon's lead compound, aminoguanidine, which is now in human clinical trials, and possibly other compounds to include the major markets of Europe. Alteon has retained the option to joint market these compounds with Marion Merrell Dow in those primary European markets, as well as in North America. In selected other markets of Europe, and in Australia, New Zealand, Mexico and Brazil, Marion Merrell Dow will have an exclusive license to market the compounds.
 Alteon said it will receive $5,000,000 for the exercise of the option. The company indicated that the agreement provides the development and marketing mechanisms for its to exploit directly its principal technologies on an international basis in partnership with Marion Merrell Dow.
 Alteon, which completed its initial public offering in November 1991, also has a pre-clinical research and development collaboration for these products with Yamanouchi Pharmaceutical Co., Ltd. of Tokyo. Yamanouchi has an exclusive license in Japan and three other Asian markets.
 Alteon is a development stage pharmaceutical company engaged in the discovery and development of products for the treatment of the complications of diabetes and aging. These products are designed to inhibit, reverse and measure damage to cells, tissues and organs caused by advanced glycosylation end-products (AGEs) which are formed as a result of glucose in the body's circulatory system.
 -0- 12/13/91
 /CONTACT: Charles A. Faden, chairman, president and CEO of Alteon, 201-784-1010; or Anthony J. Russo of Noonan/Russo Communications, 212-979-9180/
 (ALTN MKC) CO: Alteon Inc.; Marion Merrell Dow Inc. ST: New Jersey IN: MTC SU: JVN


JT-CK -- NY002 -- 2246 12/13/91 08:34 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 13, 1991
Words:370
Previous Article:ZEOS ANNOUNCES NEW LOW COST DESKTOP COMPUTER LINE
Next Article:UNITED AIRLINES AND IAM REACH TENTATIVE LABOR AGREEMENT
Topics:


Related Articles
IMMULOGIC AND MARION MERRELL DOW SIGN COLLABORATION AGREEMENT TO COMMERCIALIZE IMMULOGIC'S ALLERVAX ALLERGY PRODUCTS
IMMULOGIC AND MARION MERRELL DOW SIGN FINAL ALLERVAX PRODUCT COMMERCIALIZATION AGREEMENT
SCIOS INC. AND MARION MERRELL DOW SIGN MAJOR RESEARCH AND DEVELOPMENT AGREEMENT TO DEVELOP NEW THERAPIES FOR ALZHEIMER'S DISEASE
MARION MERRELL DOW COMMITS TO MAJOR EXPANSION OF AFFYMAX ALLIANCE
MARION MERRELL DOW INC. AND MITSUBISHI KASEI CORP. ANNOUNCE NORTH AMERICAN COLLABORATION
MARION MERRELL DOW IN-LICENSES TWO DRUGS IN LATE-STAGE TRIALS FROM MERCK & CO.
SANDOZ AND MARION MERRELL DOW ANNOUNCE CO-PROMOTION ARRANGEMENT
RUGBY LABORATORIES REACHES AGREEMENT TO REGISTER AND SELL PRODUCTS IN RUSSIA
ONCOGENE SCIENCE, INC. AND MARION MERRELL DOW COLLABORATIVE PROGRAM ADVANCES
HOECHST MARION ROUSSEL AND ALTEON TO END COLLABORATION; ALTEON TO REGAIN ALL RIGHTS TO PIMAGEDINE AND CORE TECHNOLOGY

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters